Compared to vehicle-treated controls, daily SSTR2a administration did not alter food intake, body weight, or basal/bolus maintenance insulin needs to treat hyperglycemia, but did result in a lower HbA1c level and fasting glycemia than controls after 8 daily doses, and increased glucagon response during repeated insulin-induced hypoglycemia. The gene discussed is INS; the disease is Hyperglycemia.